GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pharma-Bio Serv PBSV · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.50

+24.53%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$9.0m

FY2016FY2025

Net income

−$100,463

FY2016FY2025

Free cash flow

−$221,530

FY2016FY2025

Shareholders' equity

$11.9m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$9.0m$9.5m$17.0m$19.4m$20.1m$21.6m$19.5m$17.8m$15.6m$19.5m
Gross profit$2.9m$2.5m$5.1m$4.9m$5.4m$6.7m$6.2m$5.7m$3.6m$5.8m
Operating income−$637,662−$1.3m$1.1m$1.2m−$3.9m$2.2m$1.7m$1.1m−$1.4m−$91,759
Net income−$100,463−$777,619$1.3m$1.0m−$2.1m$2.1m$2.1m$1.3m−$1.4m−$256,575
Diluted earnings per share-0.00-0.030.060.04-0.090.090.090.06-0.06-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$13.7m$16.3m$19.9m$20.7m$23.9m$29.9m$26.6m$25.4m$22.4m$24.0m
Cash and short-term investments—————$17.1m$15.5m$16.1m$11.8m$13.8m
Total liabilities$1.7m$2.6m$3.8m$4.1m$5.0m$7.2m$6.0m$5.1m$1.6m$2.2m
Debt—————$1.9m$78,109$59,795$63,042$31,020
Shareholders' equity$11.9m$13.7m$16.1m$16.6m$18.9m$22.7m$20.6m$20.3m$20.7m$21.8m
Shares outstanding23m23m23m23m23m23m23m23m23m23m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$214,886−$566,701$1.9m$592,457$804,842$1.5m−$2.2m$3.7m−$1.7m$709,653
Capital spending−$6,644−$159,743−$7,251−$19,269−$10,845−$55,657−$57,379−$122,009−$56,973−$1.8m
Free cash flow−$221,530−$726,444$1.9m$573,188$793,997$1.5m−$2.3m$3.6m−$1.8m−$1.1m
Dividends paid−$1.7m−$1.7m−$1.7m−$3.4m−$1.7m−$1.7m−$1.7m−$1.7m−$1.7m−$1.7m

Latest quarters

By quarter end

Jul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024
Revenue$2.3m$2.7m$2.3m$2.1m$2.0m$2.4m$2.5m$2.3m
Gross profit$691,734$902,041$722,374$748,935$574,262$818,726$768,109$726,570
Operating income−$71,812$144,676−$94,535−$133,272−$313,877−$98,322−$92,191−$154,130
Net income−$14,219$232,986$32,860−$102−$204,250$95,353$8,536$16,111
Diluted earnings per share-0.000.010.00-0.00-0.010.000.000.00
Total assets$11.4m$11.5m$13.5m$13.7m$13.6m$13.9m$16.1m$16.3m
Shareholders' equity$10.4m$10.5m$10.2m$11.9m$11.9m$12.1m$12.0m$13.7m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-22.6%-16.0%-9.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin29.3%28.0%28.4%29.2%
Operating margin-10.4%0.7%-1.3%0.9%
Net margin-4.7%2.6%1.5%2.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-136.8-16.218.418.0-11.316.39.618.0-8.5-88.8
Price to sales1.51.31.40.91.21.61.01.30.81.2

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-2%-44%34%-29%-23%53%-14%84%-37%-13%

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 28 Feb 2025.

FY2025FY2024FY2023FY2022FY2021FY2019FY2018
Paid in the year0.0750.0750.0750.150.0750.0750.075

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.